Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Efalizumab: an overview.

Craig L Leonardi¹

¹Department of Dermatology, Saint Louis University School of Medicine, 1034 South Brentwood Boulevard, Suite 600, St Louis, MO 63117, USA.

Journal of the American Academy of Dermatology

|August 2, 2003

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Development of Psoriasis Assessment Tools Among Patients in the CorEvitas Psoriasis Registry.

Journal of psoriasis and psoriatic arthritis·2024

Same author

Wolf's isotopic response of lichen planus following contact dermatitis.

JAAD case reports·2022

Same author

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.

Advances in therapy·2022

Same author

Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2).

Journal of drugs in dermatology : JDD·2021

Same author

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.

Drug safety·2021

Same author

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2021

Same journal

Comparative Alopecia Outcomes After Copper and Hormonal Intrauterine Device Placement: A TriNetX Database Retrospective Cohort Study.

Journal of the American Academy of Dermatology·2026

Same journal

Uncovering a Dual Th17/Type 2 Transcriptomic Endotype in Psoriasis.

Journal of the American Academy of Dermatology·2026

Same journal

Dermatologic conditions associated with HIV among US adults across different racial and ethnic groups: A retrospective cohort study using TriNetX.

Journal of the American Academy of Dermatology·2026

Same journal

Ethical Considerations in Same-Day Surgical Treatment of a High-Risk, Poorly Differentiated Squamous Cell Carcinoma.

Journal of the American Academy of Dermatology·2026

Same journal

The Ethics of the Handshake in Dermatology.

Journal of the American Academy of Dermatology·2026

Same journal

Dermatology images: Hidradenitis suppurativa.

Journal of the American Academy of Dermatology·2026

See all related articles

Efalizumab, a targeted T cell modulator, effectively treats moderate to severe plaque psoriasis with rapid clinical benefits. Extended treatment maintains and improves responses, showing good tolerability in patients.

Area of Science:

Immunology
Dermatology
Pharmacology

Background:

Plaque psoriasis is a chronic inflammatory skin condition.
Current treatments have limitations in efficacy and safety.
Targeted therapies offer new treatment avenues.

Purpose of the Study:

To evaluate the efficacy and safety of efalizumab for plaque psoriasis.
To determine the optimal duration of efalizumab treatment.
To assess the onset and maintenance of clinical response.

Main Methods:

Phase I, II, and III clinical trials were conducted.
Efalizumab (anti-CD11a) was administered weekly.
Histologic and clinical outcomes were assessed.

Related Experiment Videos

Main Results:

Efalizumab demonstrated histologic improvement and clinical benefit.
Significant improvements were observed within 4 weeks of treatment.
Extending treatment to 24 weeks maintained and improved initial responses.
Efalizumab therapy was generally well tolerated at both 12 and 24 weeks.

Conclusions:

Efalizumab is a safe and effective treatment for moderate to severe plaque psoriasis.
Rapid onset and sustained response are key benefits.
Further studies are ongoing to optimize dosing and administration.